Zetapaxovir (2)
Zetapaxovir-2
Zetapaxovir (2)
Zetapaxovir-2

Zetapaxovir 

Pharmaceutical

Product Details:

Brand Name: Zetapaxovir  Capsule.

Composition:

Each Zetapaxovir  Capsule, co-packaged for oral use  contains:

Nirmatrelvir ………………………………150 mg

Ritonavir     ………………………………100 mg

Therapeutic Indications :               

  • is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Dosage and Administration:  

  • The recommended dosage is 300 mg (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) all taken together orally every 12 hours for 5 days.
  • Zetapaxovir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset. Completion of the full 5-day treatment course is recommended even if the patient requires hospitalization due to severe or critical COVID-19 after starting treatment with Zetapaxovir.
  • If the patient misses a dose of Zetapaxovir within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.

Contraindications:         

  • History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. (4)
  • Co-administration with drugs is highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. (4, 7.3)
  • Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.

Warnings and precautions:

  • The concomitant use of Zetapaxovir and certain other drugs may result in potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions.
  • Allergic Reactions/Hypersensitivity: Hypersensitivity reactions have been reported with Zetapaxovir. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue Zetapaxovir and initiate appropriate medications and/or supportive care.
  • Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir.
  • HIV-1 Drug Resistance: Zetapaxovir use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.

Undesirable Effects:        

  • Adverse events (incidence ≥1% and ≥5 subject difference) were dysgeusia, diarrhea, hypertension, and myalgia

Pharmacological Properties:

Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nsp5 protease. Inhibition of SARS-CoV-2 Mpro renders it incapable of processing polyprotein precursors, preventing viral replication. Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 Mpro in a biochemical assay with a Ki value of 3.1 nM and an IC50 value of 19.2 nM. Nirmatrelvir was found to bind directly to the SARS-CoV-2 Mpro active site by X-ray crystallography.

Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir

Packaging:              

Zetapaxovir capsule: Box containing 5 blisters of daily dose of ( 4 capsule of  Nirmatrelvir and 2 capsules of Ritonavir ).